NEW YORK, Jan. 29 (GenomeWeb News) - BioTrove said today it has raised $10.9 million in financing to develop its Living Chip technology and assays.
Investors in the round include Catalyst Health and Technology Partners, CB Health Ventures, Zero Stage Capital, and BioFrontier Partners.
The company, based in Woburn, Mass., is aiming its Living Chip technology, a nano-fluidics platform, at analysis of genomic, proteomic, cellular, and other biochemical samples. It also is developing a mass spectrometry service, Momentum Assay Development and Screening, for microliter-scale assays and screening.
The company also said it has appointed to its board of directors Ben Bronstein, amanaging director at Zero Stage Capital.